Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of
raloxifene and should not be coadministered with EVISTA.
Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic
conditions. However, 10% decreases in prothrombin time have been observed in single-dose studies. If EVISTA is given
concurrently with warfarin, prothrombin time should be monitored.
Other Highly Protein-Bound Drugs: Evista is more than 95% bound to plasma proteins. In vitro,
raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. Caution should be used when EVISTA is
coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen,
diazepam, and diazoxide.
See also CLINICAL PHARMACOLOGY, Drug-Drug Interactions